INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Institute
Hamad Medical Corporation
Doha, QatarPublications in collaboration with researchers from Hamad Medical Corporation (9)
2024
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study
JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387
-
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Infection
2023
-
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
Haematologica, Vol. 108, Núm. 1, pp. 22-33
-
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
eClinicalMedicine, Vol. 65
2022
2021
-
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Journal of Hematology and Oncology, Vol. 14, Núm. 1
2020
-
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
Leukemia, Vol. 34, Núm. 11, pp. 3007-3018
-
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
Leukemia, Vol. 34, Núm. 2, pp. 589-603